The Food and Drug Administration (FDA) is proposing the makers of metal-on-metal hip implants take greater responsibility by proving their products are safe prior to marketing them. Already an established subject of concern due to adverse reactions, metal-on-metal hip implants gained greater scrutiny when a recent FDA review found the artificial hips may pose problems for women and those who received larger-size implants. The FDA order proposed to require the filing of premarket approval application (PMA) or a notice of completion of a product development protocol (PDP) for metal-on-metal hip implants (January 17, 2013).
To continue reading this article or issue you must be a paid subscriber.
Sign in
